Rhythm Pharmaceuticals (RYTM) Could Be 33% Undervalued On Its Genetic Obesity Story

Rhythm Pharmaceuticals: What Five Years Of Outperformance Signal For Investors

Rhythm Pharmaceuticals (RYTM) drew fresh attention after long term holders saw very strong gains over five years, with the stock materially outperforming the broader market and turning a hypothetical US$100 stake into US$767.39.

That performance sits alongside a current share price of US$87.86 and a market value of about US$6.09b. This raises a clear question for investors: how does that track record line up with Rhythm Pharmaceuticals’ current business profile and risks today?

Rhythm Pharmaceuticals’ recent trading tells a different story to its five year surge, with the share price down 14.64% year to date and posting weaker 30 and 90 day share price returns, even as the three and five year total shareholder returns remain very strong. That softer near term momentum, capped by a 1 day share price gain of 1.35% to US$89.64, hints that investors are reassessing both the growth potential of IMCIVREE and the broader pipeline in light of current risks and the valuation implied by a US$6.09b market value.

Scan 20 high quality undiscovered gems that, like Rhythm Pharmaceuticals, sit at the intersection of specialist science and notable share price moves over the past few years.

Analyst targets and intrinsic models sit well above Rhythm Pharmaceuticals’ recent US$89.64 close, yet the stock has slipped over the past year. Is that a bargain signal, or a warning that the market’s caution is justified?

Most Popular Narrative: 33% Undervalued

Rhythm Pharmaceuticals’ most followed valuation story pegs fair value at $134.00 per share, which sits well above the recent $89.64 close and frames the past five year share price surge as only part of the picture according to peter_4mgsy.

Rhythm Pharmaceuticals is a commercial-stage company targeting orphan neuroendocrine disorders linked to MC4R pathway dysfunction (genetic obesity). Having expanded from one disorder to multiple approved indications, the company has additional opportunities ahead to expand its portfolio.

See why 5 investors see Rhythm Pharmaceuticals as 33% undervalued.

Result: Fair Value of $134.00 (UNDERVALUED)

Still, that upbeat Rhythm Pharmaceuticals narrative depends on continued demand for IMCIVREE and clean clinical readouts, and any safety setbacks or weaker uptake could quickly challenge it.

Find out about the key risks to this Rhythm Pharmaceuticals narrative.

Another View: Rhythm Pharmaceuticals Looks Expensive On Sales

There is a catch. On a simple P/S lens, Rhythm Pharmaceuticals trades at 25.7x, while the fair ratio sits at 16.3x, the US Biotechs industry averages 12.3x, and peer companies are around 8.4x. That gap points to real valuation risk if sentiment shifts away from growth stories.

For investors who want to see how hard numbers can challenge or support that sort of premium, it is worth checking the fuller breakdown in the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Feeling mixed after that valuation split on Rhythm Pharmaceuticals and its premium P/S ratio? Move fast, review the numbers yourself, then weigh those positives in the 3 key rewards.

Looking For More Ideas Beyond Rhythm Pharmaceuticals?

Do not stop your research at Rhythm Pharmaceuticals. Broaden your watchlist with focused stock ideas built from clear data so you can compare opportunities side by side.

• Target companies with strong fundamentals and attractive pricing by reviewing the 27 high quality undervalued stocks before sentiment shifts and valuations adjust.
• Strengthen your capital protection by scanning the 31 resilient stocks with low risk scores and concentrate on resilient businesses with lower risk scores.
• Hunt for less crowded opportunities by checking the 20 high quality undiscovered gems and see which under-the-radar stocks match your quality filters.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com